drugset / Trial / NCT01816321

Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial

NCT01816321

RandomizedParallel-groupOpen-labelTreatment

Summary

In combination with the existing literature, previous work indicates that 1) women with poor ovarian response fulfilling the "Bologna criteria" have very low pregnancy rates, irrespective of age 2) current treatment protocols demonstrate ongoing pregnancy rates that do not exceed 8.5% and 3) corifollitropin alfa followed by hpHMG might increase ongoing pregnancy rates in young patients (\<40years old) fulfilling the criteria. These findings provide a strong rationale for a definitive large RCT. The COMPORT study will provide conclusive evidence regarding the superiority or not of this novel protocol with corifollitropin alfa followed by hpHMG for the treatment of young poor ovarian responders fulfilling the Bologna criteria.

Timeline

Start
2013-03
Primary completion
2016-05
Completion
2016-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 150 ug
Comparator Gonal-f Protein / enzyme biologic 300 iu
Subject Menopur Protein / enzyme biologic 300 iu
Background Ganirelix Protein / enzyme biologic 0.25 mg